Keystone Pharmaceuticals

CStone Pharmaceuticals is a leading biopharmaceutical company focused on the discovery, development, and commercialization of innovative oncology therapies. The company has established a robust pipeline of over 15 drug candidates, including several late-stage assets and multiple approved products such as sugemalimab (PD-L1) and avapritinib. CStone employs a strategic model combining in-house research with global partnerships, collaborating with industry leaders like Pfizer, Blueprint Medicines, and Servier to bring precision medicines and immuno-oncology treatments to patients. Headquartered in Suzhou, China, CStone is publicly traded on the Hong Kong Stock Exchange and is recognized for its rapid clinical development capabilities and strong presence in the Asian oncology market.